NMRA icon

Neumora Therapeutics

134 hedge funds and large institutions have $852M invested in Neumora Therapeutics in 2024 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding:

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more ownership

Funds ownership:

4% more call options, than puts

Call options by funds: $64.8M | Put options by funds: $62.2M

6% less capital invested

Capital invested by funds: $906M → $852M (-$54M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
134
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$64.8M
Puts
$62.2M
Net Calls
Net Calls Change

Top Buyers

1 +$36.4M
2 +$34.3M
3 +$19M
4
JPMorgan Chase & Co
JPMorgan Chase & Co
New York
+$14.2M
5
BlackRock
BlackRock
New York
+$9.75M

Top Sellers

1 -$23.8M
2 -$10.7M
3 -$8.9M
4
O
OrbiMed
New York
-$7.37M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.3M
Name Holding Trade Value Shares
Change
Change in
Stake
76
$346K
77
$332K
78
$332K
79
$286K
80
$281K
81
$276K
82
$271K
83
$265K
84
$256K
85
$231K
86
$230K
87
$227K
88
$221K
89
$212K
90
$196K
91
$185K
92
$180K
93
$177K
94
$172K
95
$150K
96
$143K
97
$137K
98
$135K
99
$123K
100
$117K